SABS SAB Biotherapeutics, Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company advancing a class of immunotherapies based on its human polyclonal antibodies. It develops fully human antibodies produced from transchromosomic (Tc) bovine herds targeted at addressing specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer.

$0.70  +0.02 (3.19%)
As of 02/01/2023 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  02/09/2021
Outstanding shares:  43,030,885
Average volume:  61,756
Market cap:   $29,708,523
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BP2DGG9
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy